Ranibizumab
DrugWikipedia
7
MENTIONS
5
EPISODES
4
PODCASTS
Search complete. 7 mentions across 5 episodes found for "Ranibizumab".
Oct 1, 2026
John KitchensHOST
And it's also another pathway that I think we need a lot of education around, this Wnt-Norin pathway.
John KitchensHOST
And this study basically showed non-inferiority to lucentis or ranibizumab every month.
John KitchensHOST
And that was the 0.5 milligrams.
John KitchensHOST
So the higher dose, the internationally available dose for diabetic macular edema showed non-inferiority.
J. Fernando ArevaloGUEST
So there are some things that need to be improved about therapy of patients with proliferative diabetic retinopathy.
J. Fernando ArevaloGUEST
And we have a look of anti-BGF therapy And there are several studies that have been done that have shown how anti-BGF with Ranibizumab or Aflivercept in protocol S and Clarity are similar to PRP or non-inferior in terms of visual acuity, but also in terms of how they control the retinal neovascularization in PDR.
J. Fernando ArevaloGUEST
However, when you look at those studies and the trend that it has brought with a lot of people in the U.S., especially using anti-BGF therapy alone for the therapy of PDR, we find that there are some risks.
J. Fernando ArevaloGUEST
Several studies have also demonstrated that when patients are lost to follow-up, there are significant consequences to that loss to follow-up with patients developing traction and retinal detachment and vitreous hemorrhage.
Praveen DuggalGUEST
What's, what do you, what problem are you solving for?" The problem is this: what we've come to realize is two things.
Praveen DuggalGUEST
You know, one is that despite having these incredible treatments, which at that time was Lucentis and then, and then Eylea came, and now we have the, the second version of both of those drugs, but they still block that one receptor.
Praveen DuggalGUEST
Despite having these phenomenal, incredibly safe drugs and a way to administer them which has been proven to be effective and safe with time, in this country, and this is the US, uh, you know, the richest country in the world, 40% of patients actually drop out in the first year.
MeganHOST
Wow.
9 MINS LATER
MeganHOST
How does it feel to be at this stage?
Praveen DuggalGUEST
That question is actually more profound than, than I think you even anticipate because macular degeneration is actually in my family.
Praveen DuggalGUEST
My father, before he passed away, was blind in one eye because of wet macular degeneration and was on Lucentis for almost 25 years.
Praveen DuggalGUEST
I remember that was his only eye, and when he was in, when he was bedridden in the last couple of years of his life, you know, it took us four hours to transport him to get a Lucentis injection.
John KitchensHOST
Maybe this gives us a chance to actually invoke some additional improvement in those patients.
Scott KrzywonosHOST
John, was there ever a theoretical risk you think that Remig-Remig was going to have these higher rates of PDR and vitreous hemorrhage? And if so, why not just make it a combination trial in the first place? Just have Remig-Remig in combination with Ranibizumab versus Ranibizumab monotherapy?
John KitchensHOST
Yeah, so I think there was obviously this knowledge that this Wnt-Norin pathway could actually increase this angiogenic signal in ischemic retina.
John KitchensHOST
But the reason why not to do it in combination with anti-VEGF therapy, I think if we go back and look at a couple of the phase two studies, the Regeneron did.
Sarah WelchGUEST
Yes, I think, I mean, when we listen to patients, people often say sight is one of the things that they prioritise the most.
Sarah WelchGUEST
And one of the things we find within ophthalmology is that our our demand increases more than population partly because as you say the ageing population also because of the increasing number of people with diabetes and also I guess the good news is that 20 years ago we couldn't do anything for age related macular degeneration and now we've got these wonderful drugs like Vastin and Lucentis and things which can really improve things but the downside of them is that People need to come really regularly, and if their appointments are not missed or stretched out or they're longer than a week or two overdue, they can lose vision.
Kerre WoodhamHOST
Problems in ophthalmology have been going on for years, though.
Kerre WoodhamHOST
My memory was jogged.